当前位置:首页 - 行情中心 - 药康生物(688046) - 财务分析 - 现金流量表

药康生物

(688046)

  

流通市值:150.54亿  总市值:150.54亿
流通股本:4.10亿   总股本:4.10亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金425,791,575.31166,842,991.98812,900,801.53513,933,061.3
  收到的税费返还--11,382.7211,382.72
  收到其他与经营活动有关的现金13,337,298.69,813,127.2332,315,320.6218,342,467.76
  经营活动现金流入小计439,128,873.91176,656,119.21845,227,504.87532,286,911.78
  购买商品、接受劳务支付的现金114,676,738.5252,249,496.8168,542,140.18129,978,572.52
  支付给职工以及为职工支付的现金183,095,223.53105,168,775.91313,880,735.66243,405,353.33
  支付的各项税费21,724,250.058,616,224.8129,293,515.5717,131,592.7
  支付其他与经营活动有关的现金31,597,679.9614,711,535.43106,484,116.4154,597,068.56
  经营活动现金流出小计351,093,892.06180,746,032.95618,200,507.82445,112,587.11
  经营活动产生的现金流量净额88,034,981.85-4,089,913.74227,026,997.0587,174,324.67
二、投资活动产生的现金流量:
  收回投资收到的现金11,657,534.2511,657,534.25--
  取得投资收益收到的现金9,697,076.166,094,697.2617,238,865.0310,402,185.29
  处置固定资产、无形资产和其他长期资产收回的现金净额--155,392.4313,000
  收到的其他与投资活动有关的现金1,561,464,946.58922,200,041.712,549,316,558.351,735,548,888.9
  投资活动现金流入小计1,582,819,556.99939,952,273.222,566,710,815.811,745,964,074.19
  购建固定资产、无形资产和其他长期资产支付的现金35,828,773.2415,579,872.11104,989,859.4495,760,358.51
  投资支付的现金--15,510,00015,510,000
  支付其他与投资活动有关的现金1,650,956,474.65954,112,928.442,912,791,174.072,228,152,969.18
  投资活动现金流出小计1,686,785,247.89969,692,800.553,033,291,033.512,339,423,327.69
  投资活动产生的现金流量净额-103,965,690.9-29,740,527.33-466,580,217.7-593,459,253.5
三、筹资活动产生的现金流量:
  吸收投资收到的现金--14,524,800-
  取得借款收到的现金100,911,178.6729,210,000298,490,282.88255,168,663.99
  收到其他与筹资活动有关的现金---11,249,600
  筹资活动现金流入小计100,911,178.6729,210,000313,015,082.88266,418,263.99
  偿还债务支付的现金151,745,005.158,418,663.99199,209,444.4487,902,777.78
  分配股利、利润或偿付利息支付的现金78,253,637.54353,162.7661,223,026.8748,030,922.51
  支付其他与筹资活动有关的现金11,122,276.013,684,722.6925,688,891.921,178,064.44
  筹资活动现金流出小计241,120,918.6562,456,549.44286,121,363.21157,111,764.73
  筹资活动产生的现金流量净额-140,209,739.98-33,246,549.4426,893,719.67109,306,499.26
四、汇率变动对现金及现金等价物的影响-7,879,409.4-4,357,164.26-2,614,681.6754,614.88
  现金及现金等价物净增加额平衡项目000-0.01
五、现金及现金等价物净增加额-164,019,858.43-71,434,154.77-215,274,182.65-396,923,814.7
  加:期初现金及现金等价物余额485,941,260.08485,912,238.51701,215,442.73701,215,442.73
  期末现金及现金等价物余额平衡项目0-0.0100
  期末现金及现金等价物余额321,921,401.65414,478,083.73485,941,260.08304,291,628.03
补充资料:
  净利润110,814,393.33-142,636,806.31-
  资产减值准备9,872,499.2-19,772,588.85-
  固定资产和投资性房地产折旧39,411,039.79-70,235,754.1-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧39,411,039.79-70,235,754.1-
  无形资产摊销2,661,472.01-4,887,300.79-
  长期待摊费用摊销3,169,872.02-11,805,027.82-
  处置固定资产、无形资产和其他长期资产的损失1,230.7-36,167.9-
  公允价值变动损失-926,317.11--693,494.32-
  财务费用8,924,463.68-6,984,234.86-
  投资损失-8,399,582.98--8,746,616.58-
  递延所得税-2,028,804.96-2,573,559.42-
  其中:递延所得税资产减少-2,350,339.14-2,843,244.72-
    递延所得税负债增加321,534.18--269,685.3-
  存货的减少-22,916,813.02--18,764,386.12-
  经营性应收项目的减少-37,427,749.93--56,606,788.09-
  经营性应付项目的增加-35,642,758.02-22,202,617.21-
  其他6,251,801.92-7,822,656.34-
  不涉及现金收支的投资和筹资活动金额其他项目--68,531,740.14-
  现金的期末余额321,921,401.65-485,941,260.08-
  减:现金的期初余额485,941,260.08-701,215,442.73-
  现金及现金等价物的净增加额-164,019,858.43--215,274,182.65-
公告日期2026-08-202026-04-232026-04-232025-10-23
审计意见(境内)标准无保留意见
TOP↑